Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis

@article{Deacon2012GlycaemicEO,
  title={Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis},
  author={C. Deacon and E. Mannucci and B. Ahr{\'e}n},
  journal={Diabetes},
  year={2012},
  volume={14}
}
  • C. Deacon, E. Mannucci, B. Ahrén
  • Published 2012
  • Medicine
  • Diabetes
  • Aims: During recent years, two strategies of incretin‐based therapy [glucagon‐like peptide‐1 (GLP‐1) receptor agonism and dipeptidyl peptidase‐4 (DPP‐4) inhibition] have entered the market for pharmacological management of type 2 diabetes. A main indication for this therapy is as add‐on to on‐going metformin therapy in subjects with type 2 diabetes who have insufficient glycaemic control with metformin alone. The aim of this study was to compare improvements in glycaemic control and changes in… CONTINUE READING
    159 Citations
    Combination therapy of dipeptidyl peptidase‐4 inhibitors and metformin in type 2 diabetes: rationale and evidence
    • 32
    Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
    • 14
    • Highly Influenced
    Incretin therapy and its effect on body weight in patients with diabetes.
    • M. Lind
    • Medicine
    • Primary care diabetes
    • 2012
    • 18
    Is there a place for incretin therapies in obesity and prediabetes?
    • 32
    Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.
    • G. Umpierrez, L. Meneghini
    • Medicine
    • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
    • 2013
    • 10

    References

    SHOWING 1-10 OF 44 REFERENCES
    Dipeptidyl Peptidase‐4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP‐1
    • 149
    Incretin‐based therapies – review of the physiology, pharmacology and emerging clinical experience
    • 65
    Incretin based therapies for type 2 diabetes mellitus.
    • 177
    Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
    • B. Ahrén
    • Medicine
    • Vascular health and risk management
    • 2008
    • 56
    • PDF
    Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
    • B. Ahrén
    • Medicine
    • Diabetes, metabolic syndrome and obesity : targets and therapy
    • 2010
    • 40
    • PDF